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Editorial
Why do immunology research in hemophilia?
In this special issue of Cellular Immunology, we highlight the
work of researchers investigating the immune response to factor
VIII (FVIII) in hemophilia. Hemophilia is a relatively rare disease
with an incidence of 1/5000 males. Why is it important to investi-
gate the immune response in a relatively rare disease? Why study
any orphan monogenic disease? The answer lies in immunology!
Hemophilia A is an x-linked disease caused by a variety of
mutations (deletions, inversions, missense, etc.) in the gene for
the coagulation protein FVIII. Because these patients lack FVIII, this
leads to bleeding issues that can have life-long morbidity conse-
quences, e.g. joint arthropathy resulting from repeated bleeds. We
know how to treat this disease with prophylactic and therapeutic
injections of human recombinant or plasma-derived FVIII to restore
near-normal clotting times. However, up to 30% of hemophilia A
patients produce antibodies to FVIII that neutralize the efficacy of
this bio-therapeutic. These antibodies are referred to by clinicians
as ‘‘inhibitors” because they inhibit the pro-coagulant function of
FVIII. Clearly, many severe hemophilia A patients lack central
tolerance to this human protein because they most likely never
saw it during the development of the immune system: a beautiful
natural example of acquired self-tolerance.
Once patients develop inhibitors, there is currently only one
major therapy, referred to as ‘‘ITI”, short for Immune Tolerance
Induction. Basically this involves repeated high doses of FVIII.
Aside from being expensive, ITI often fails in patients with high
titered inhibitors. Clearly, novel approaches for tolerance are
needed; several articles in this issue address this problem.
So many unanswered questions remain: Why do some patients
never make a clinically significant immune response? Why is FVIII
so immunogenic when given intravenously? How can we prevent
or reverse inhibitor formation?
We offer these research and review articles as state-of-the-art
answers to these ‘‘Why?” and ‘‘How” questions. I also recommend
the advice of Professor E.O. Wilson [1] in his recent book ‘‘Letters to
a Young Scientist”: find a niche and excel in it. Hemophilia
immunology and immune tolerance approaches to monogenic
diseases is such a niche.
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